Establishment of a diagnostic model to distinguish coronavirus disease 2019 from influenza A based on laboratory findings

TL;DR

This study developed a diagnostic model using laboratory findings to accurately distinguish COVID-19 from influenza A, aiding in precise clinical diagnosis.

Contribution

The paper introduces a novel laboratory-based diagnostic model that combines specific blood parameters to differentiate COVID-19 from influenza A.

Findings

The model achieved high accuracy in distinguishing the two diseases.

A/G, TBIL, and HCT are key indicators for diagnosis.

External validation confirmed the model's robustness.

Abstract

Background: Coronavirus disease 2019 (COVID-19) and Influenza A are common disease caused by viral infection. The clinical symptoms and transmission routes of the two diseases are similar. However, there are no relevant studies on laboratory diagnostic models to discriminate COVID-19 and influenza A. This study aims at establishing a signature of laboratory findings to tell patients with COVID-19 apart from those with influenza A perfectly. Materials: In this study, 56 COVID-19 patients and 54 influenza A patients were included. Laboratory findings, epidemiological characteristics and demographic data were obtained from electronic medical record databases. Elastic network models, followed by a stepwise logistic regression model were implemented to identify indicators capable of discriminating COVID-19 and influenza A. A nomogram is diagramed to show the resulting discriminative model. Results: The majority of hematological and biochemical parameters in COVID-19 patients were significantly different from those in influenza A patients. In the final model, albumin/globulin (A/G), total bilirubin (TBIL) and erythrocyte specific volume (HCT) were selected as predictors. Using an external dataset, the model was validated to perform well. Conclusion: A diagnostic model of laboratory findings was established, in which A/G, TBIL and HCT were included as highly relevant indicators for the segmentation of COVID-19 and influenza A, providing a complimentary means for the precise diagnosis of these two diseases.